Chronic Constipation: Drugs That Cause It and Drugs That Treat It

Why So Many Medications Cause Chronic Constipation

Drug-induced constipation accounts for a sizable fraction of chronic cases, yet prescribers often underestimate the risk. The American College of Gastroenterology (ACG) 2021 guideline on chronic constipation lists medication review as a mandatory first step in evaluation [1]. Four distinct pharmacologic mechanisms explain why certain drug classes slow the gut.

Opioid Receptor Activation in the Enteric Nervous System

Opioids bind mu-receptors on enteric neurons, reducing peristaltic contractions and increasing fluid reabsorption. The result is hard, infrequent stools. Opioid-induced constipation (OIC) occurs in 40 to 80 percent of patients on chronic opioid therapy [2]. Unlike most opioid side effects, constipation does not improve with tolerance. Patients on long-term morphine, oxycodone, hydrocodone, or fentanyl should be started on a bowel regimen at the same time as the opioid, per the AGA's 2019 clinical practice update [3].

Anticholinergic Blockade

Muscarinic receptor antagonists reduce smooth-muscle contractility throughout the GI tract. Drugs with high anticholinergic burden include oxybutynin, tolterodine, diphenhydramine, tricyclic antidepressants (amitriptyline, nortriptyline), and first-generation antipsychotics. A systematic review in Age and Ageing found that anticholinergic burden scores above 3 doubled the odds of constipation in adults over age 65 [4].

Calcium Channel Blockers and Smooth-Muscle Relaxation

Verapamil is the most constipating antihypertensive in clinical practice. It inhibits L-type calcium channels in colonic smooth muscle, producing dose-dependent slowing of transit. Constipation rates with verapamil reach 25 percent in post-marketing data. Amlodipine and diltiazem carry lower but measurable risk. Switching from verapamil to an ARB or ACE inhibitor eliminates the effect in most patients.

Iron, Calcium, and Aluminum-Based Supplements

Oral ferrous sulfate causes constipation in roughly one-third of users. The mechanism involves direct mucosal irritation and altered gut microbiota composition. Calcium carbonate (especially at doses above 1,200 mg/day) and aluminum-containing antacids similarly slow transit. When possible, switching to ferrous bisglycinate or IV iron can relieve symptoms without sacrificing hematologic targets [5].

The Full List of Drug Classes Linked to Chronic Constipation

A thorough medication reconciliation is the cheapest diagnostic test in gastroenterology. Below is a reference table of the most common offenders, organized by mechanism and typical constipation incidence.

| Drug Class | Examples | Constipation Rate | |---|---|---| | Opioid analgesics | Morphine, oxycodone, fentanyl | 40 to 80% | | Anticholinergics | Oxybutynin, amitriptyline, diphenhydramine | 20 to 40% | | Calcium channel blockers | Verapamil, diltiazem | 10 to 25% | | Iron supplements | Ferrous sulfate, ferrous fumarate | 15 to 30% | | 5-HT3 antagonists | Ondansetron, granisetron | 5 to 12% | | Antipsychotics | Clozapine, olanzapine | 15 to 60% (clozapine highest) | | Antiepileptics | Carbamazepine, gabapentin | 5 to 15% | | Diuretics | Furosemide, hydrochlorothiazide | 5 to 10% | | GLP-1 receptor agonists | Semaglutide, tirzepatide | 5 to 12% | | Aluminum antacids | Maalox, Mylanta | 10 to 20% |

Clinicians should cross-reference this table during every new-patient intake for constipation. "The most effective intervention for drug-induced constipation is to stop or switch the causative agent," the ACG 2021 guideline states [1]. When stopping is not an option, targeted prescription therapy becomes necessary.

Diagnosing Chronic Constipation: What the Criteria Actually Require

Chronic constipation is not simply "not going enough." Rome IV criteria require at least two of six symptoms (straining, lumpy/hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction, manual maneuvers, fewer than three spontaneous bowel movements per week) present for the last three months, with symptom onset at least six months before diagnosis [6].

Distinguishing CIC from OIC and IBS-C

This distinction matters because treatments differ. Chronic idiopathic constipation (CIC) responds to secretagogues and prokinetics. OIC requires peripherally acting mu-opioid receptor antagonists (PAMORAs). IBS-C shares some treatment overlap with CIC but also responds to low-dose antidepressants and dietary interventions. The AGA 2013 technical review recommends anorectal manometry and balloon expulsion testing when dyssynergic defecation is suspected [7].

When to Order Additional Testing

A colonoscopy is not required for every patient with chronic constipation. The ACG recommends colonoscopy for patients over 45 who have not had age-appropriate screening, or for those with alarm features: unintentional weight loss, rectal bleeding, family history of colon cancer, or new-onset constipation after age 50. Colonic transit studies (Sitz markers or wireless motility capsule) are second-line tests reserved for patients who fail empiric therapy.

Prescription Drugs That Treat Chronic Idiopathic Constipation

When fiber, adequate hydration, and osmotic laxatives (polyethylene glycol, lactulose) have failed, prescription drugs with specific gut targets offer the next step. The evidence base here is large and reproducible.

Linaclotide (Linzess)

Linaclotide is a guanylate cyclase-C agonist that increases intestinal chloride and water secretion. The FDA approved it in 2012 for CIC (145 mcg) and IBS-C (290 mcg). In two phase III trials (Study 01 and Study 03, combined N = 1,276), linaclotide 145 mcg produced a mean increase of 3.0 complete spontaneous bowel movements (CSBMs) per week versus 1.0 for placebo at 12 weeks (P<0.001) [8]. Diarrhea is the primary adverse event, occurring in 16 to 20 percent of patients. Taking the dose 30 minutes before breakfast on an empty stomach reduces diarrhea risk. Linaclotide carries a black-box warning against use in patients under age 6 and is not recommended in patients aged 6 to 17.

Lubiprostone (Amitiza)

Lubiprostone activates ClC-2 chloride channels on the apical membrane of intestinal epithelial cells. The FDA approved it in 2006 for CIC at 24 mcg twice daily. A key trial (N = 242) showed that 57 percent of lubiprostone patients had a spontaneous bowel movement within 24 hours of the first dose, compared with 37 percent on placebo [9]. Nausea affects roughly 30 percent of patients, a limiting factor. Taking it with food reduces nausea significantly. Lubiprostone also holds an FDA indication for OIC in adults with chronic non-cancer pain at a lower dose (24 mcg twice daily).

Plecanatide (Trulance)

Plecanatide is a second guanylate cyclase-C agonist, dosed at 3 mg once daily. Its phase III program (two trials, combined N = 2,612) demonstrated a statistically significant increase in CSBMs versus placebo, with a diarrhea rate of only 5 percent, roughly one-third the rate seen with linaclotide [10]. This makes plecanatide a reasonable option for patients who discontinued linaclotide due to diarrhea.

Prucalopride (Motegrity)

Prucalopride is a selective 5-HT4 receptor agonist that stimulates colonic high-amplitude propagating contractions. The FDA approved it in 2018. Three phase III trials (N = 1,999 combined) showed that prucalopride 2 mg daily produced three or more CSBMs per week in 24 percent of patients versus 12 percent on placebo over 12 weeks [11]. Unlike older 5-HT4 agonists (cisapride, tegaserod), prucalopride has no signal for cardiac arrhythmia. Headache (reported in 10 to 15 percent) is the most common adverse event and typically resolves within the first week.

Tegaserod (Zelnorm, Restricted)

The FDA re-approved tegaserod in 2019 with a narrow indication: IBS-C in women under 65 without cardiovascular risk factors. Its prior withdrawal was due to a small cardiovascular signal in post-marketing data. Given the restrictions, tegaserod is rarely prescribed today.

Prescription Drugs for Opioid-Induced Constipation

OIC warrants a separate pharmacologic approach because the constipation mechanism is receptor-mediated, not a motility or secretory deficit.

Naloxegol (Movantik)

Naloxegol is a PEGylated derivative of naloxone that does not cross the blood-brain barrier at therapeutic doses. It blocks peripheral mu-opioid receptors in the gut without reversing central analgesia. The KODIAC-04 and KODIAC-05 trials (combined N = 1,352) found that naloxegol 25 mg daily produced a response (three or more SBMs per week with an increase of one or more from baseline) in 44 percent of patients versus 29 percent on placebo (P<0.001) [12]. The recommended dose is 25 mg once daily on an empty stomach, at least one hour before the first meal. It should not be co-administered with strong CYP3A4 inhibitors.

Methylnaltrexone (Relistor)

Methylnaltrexone is a quaternary amine that cannot cross the blood-brain barrier. It is available as a subcutaneous injection (12 mg every other day) or oral tablet (450 mg daily). In a key trial (N = 133), 48 percent of methylnaltrexone patients had a rescue-free bowel movement within four hours of the first dose, compared with 15 percent on placebo [13]. It holds FDA approval for OIC in both cancer and non-cancer pain settings.

Naldemedine (Symproic)

Naldemedine 0.2 mg daily is the newest PAMORA. The COMPOSE-1 and COMPOSE-2 trials (combined N = 1,095) showed a response rate of 48 to 53 percent versus 34 to 37 percent for placebo [14]. Its oral formulation and once-daily dosing make it a practical alternative to subcutaneous methylnaltrexone.

Combining and Sequencing Treatments: A Practical Algorithm

No single drug works for every patient. The AGA and ACG guidelines both recommend a stepwise approach.

Step 1: Remove or Switch the Causative Agent

This step alone resolves constipation in a meaningful proportion of patients. If an opioid cannot be stopped, rotate to a lower-constipation formulation (transdermal buprenorphine produces less constipation than oral morphine equivalents).

Step 2: Optimize Lifestyle and Over-the-Counter Options

Polyethylene glycol (PEG 3350) at 17 g daily is the best-studied osmotic laxative and is first-line per both ACG and AGA [1, 7]. Fiber supplementation (psyllium, 5 to 10 g daily) adds benefit for patients with low dietary fiber intake. Stimulant laxatives (bisacodyl, senna) are safe for daily use in chronic constipation. The old concern about "lazy bowel" from stimulant laxatives is not supported by evidence.

Step 3: Add a Prescription Secretagogue or Prokinetic

For CIC, linaclotide and plecanatide are first-line secretagogues, while prucalopride is first-line as a prokinetic. For OIC, naloxegol is the most commonly prescribed PAMORA. The ACG 2021 guideline gives a strong recommendation for linaclotide in CIC (quality of evidence: high) and a conditional recommendation for prucalopride (quality of evidence: moderate) [1].

Step 4: Address Dyssynergic Defecation

Up to 40 percent of patients with refractory chronic constipation have pelvic floor dyssynergia. Biofeedback therapy produces long-term symptom improvement in roughly 70 to 80 percent of these patients, outperforming laxatives in head-to-head trials [15]. This is a treatable cause that medications alone will not fix.

Emerging Therapies in Late-Stage Development

Several pipeline drugs aim to address gaps in current treatment.

Elobixibat, an ileal bile acid transporter inhibitor, is approved in Japan for chronic constipation and is in late-phase trials in the United States. It works by increasing bile acid delivery to the colon, which stimulates secretion and motility. Minesapride, a 5-HT4 agonist with a cleaner receptor profile than prucalopride, is in phase III development. Vibrating capsule devices (Active) received FDA clearance in 2022 as a non-pharmacologic alternative, using mechanical stimulation to trigger the gastrocolic reflex.

When Chronic Constipation Requires Urgent Evaluation

Most chronic constipation is functional and benign. But certain red flags demand prompt investigation. New-onset constipation after age 50 with no medication cause, rectal bleeding, unintentional weight loss exceeding 10 percent of body weight, iron-deficiency anemia, or a family history of colorectal cancer or inflammatory bowel disease should all trigger colonoscopy and laboratory workup. Acute constipation with vomiting, abdominal distension, and inability to pass gas may indicate bowel obstruction, which is a surgical emergency.

The Bristol Stool Scale remains a practical patient-facing tool: types 1 and 2 indicate constipation, types 3 and 4 are normal, and types 5 through 7 indicate loose stools. Asking patients to track their Bristol type for two weeks before a visit provides more reliable data than asking "how often do you go."